Yael Levi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yael Levi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Amalia Levy
Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health Ben‐Gurion University of the Negev Beer‐Sheva Israel
3 shared publicationsEitan Lunenfeld
Adelson School of Medicine Ariel University Ariel Israel
3 shared publicationsGali Pariente
Obstetrics and Gynecology, Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva Israel
3 shared publications- Saar Dor
Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health Ben‐Gurion University of the Negev Beer‐Sheva Israel
3 shared publications - Sharon Daniel
Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health Ben‐Gurion University of the Negev Beer‐Sheva Israel
3 shared publications Tal Michael
Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health Ben‐Gurion University of the Negev Beer‐Sheva Israel
3 shared publications
Latest Publications
- Open Access
- 29 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1834-1841
Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies
Aims: The aim of this study was to assess the risk of major congenital malformations following first‐trimester pseudoephedrine (PSE) exposure.Methods: A population‐based observational cohort study was conducted on pregnancies of women aged 15–49 years, insured by Clalit Health Services in southern Israel, who gave birth or had elective pregnancy terminations due to suspected fetal malformation at Soroka Medical Center (1999–2017). The study focused on Clarinase, a drug that contains a high dose of PSE (120 mg) and 5 mg of loratadine. Multivariable negative binomial regression models were used to evaluate the risk for major congenital malformations, adjusting for potential confounders.Results: Of 251 543 pregnancies, 313 (0.12%) were exposed to high‐dose PSE in the first trimester. PSE exposure was not associated with major congenital malformations overall (adjusted relative risk [aRR] = 0.90, 95% confidence interval [CI] 0.558–1.45; P = 0.66) or by organ system (cardiovascular: aRR = 0.938, 95% CI 0.499–1.762; central nervous system: aRR = 0.618, 95% CI 0.086–4.451; musculoskeletal: aRR = 1.800, 95% CI 0.801–4.042; gastrointestinal: aRR = 1.013, 95% CI 0.142–7.241; genitourinary: aRR = 0.704, 95% CI 0.225–2.204).Conclusions: First‐trimester PSE exposure was not an independent risk factor for major congenital malformations, either overall or by organ system.
- 29 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1834-1841
Open AccessExposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies
Aims: The aim of this study was to assess the risk of major congenital malformations following first‐trimester pseudoephedrine (PSE) exposure.Methods: A population‐based observational cohort study was conducted on pregnancies of women aged 15–49 years, insured by Clalit Health Services in southern Israel, who gave birth or had elective pregnancy terminations due to suspected fetal malformation at Soroka Medical Center (1999–2017). The study focused on Clarinase, a drug that contains a high dose of PSE (120 mg) and 5 mg of loratadine. Multivariable negative binomial regression models were used to evaluate the risk for major congenital malformations, adjusting for potential confounders.Results: Of 251 543 pregnancies, 313 (0.12%) were exposed to high‐dose PSE in the first trimester. PSE exposure was not associated with major congenital malformations overall (adjusted relative risk [aRR] = 0.90, 95% confidence interval [CI] 0.558–1.45; P = 0.66) or by organ system (cardiovascular: aRR = 0.938, 95% CI 0.499–1.762; central nervous system: aRR = 0.618, 95% CI 0.086–4.451; musculoskeletal: aRR = 1.800, 95% CI 0.801–4.042; gastrointestinal: aRR = 1.013, 95% CI 0.142–7.241; genitourinary: aRR = 0.704, 95% CI 0.225–2.204).Conclusions: First‐trimester PSE exposure was not an independent risk factor for major congenital malformations, either overall or by organ system.
- Open Access
- 16 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1834-1841
Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies
Aims: The aim of this study was to assess the risk of major congenital malformations following first‐trimester pseudoephedrine (PSE) exposure.Methods: A population‐based observational cohort study was conducted on pregnancies of women aged 15–49 years, insured by Clalit Health Services in southern Israel, who gave birth or had elective pregnancy terminations due to suspected fetal malformation at Soroka Medical Center (1999–2017). The study focused on Clarinase, a drug that contains a high dose of PSE (120 mg) and 5 mg of loratadine. Multivariable negative binomial regression models were used to evaluate the risk for major congenital malformations, adjusting for potential confounders.Results: Of 251 543 pregnancies, 313 (0.12%) were exposed to high‐dose PSE in the first trimester. PSE exposure was not associated with major congenital malformations overall (adjusted relative risk [aRR] = 0.90, 95% confidence interval [CI] 0.558–1.45; P = 0.66) or by organ system (cardiovascular: aRR = 0.938, 95% CI 0.499–1.762; central nervous system: aRR = 0.618, 95% CI 0.086–4.451; musculoskeletal: aRR = 1.800, 95% CI 0.801–4.042; gastrointestinal: aRR = 1.013, 95% CI 0.142–7.241; genitourinary: aRR = 0.704, 95% CI 0.225–2.204).Conclusions: First‐trimester PSE exposure was not an independent risk factor for major congenital malformations, either overall or by organ system.
- 16 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1834-1841
Open AccessExposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies
Aims: The aim of this study was to assess the risk of major congenital malformations following first‐trimester pseudoephedrine (PSE) exposure.Methods: A population‐based observational cohort study was conducted on pregnancies of women aged 15–49 years, insured by Clalit Health Services in southern Israel, who gave birth or had elective pregnancy terminations due to suspected fetal malformation at Soroka Medical Center (1999–2017). The study focused on Clarinase, a drug that contains a high dose of PSE (120 mg) and 5 mg of loratadine. Multivariable negative binomial regression models were used to evaluate the risk for major congenital malformations, adjusting for potential confounders.Results: Of 251 543 pregnancies, 313 (0.12%) were exposed to high‐dose PSE in the first trimester. PSE exposure was not associated with major congenital malformations overall (adjusted relative risk [aRR] = 0.90, 95% confidence interval [CI] 0.558–1.45; P = 0.66) or by organ system (cardiovascular: aRR = 0.938, 95% CI 0.499–1.762; central nervous system: aRR = 0.618, 95% CI 0.086–4.451; musculoskeletal: aRR = 1.800, 95% CI 0.801–4.042; gastrointestinal: aRR = 1.013, 95% CI 0.142–7.241; genitourinary: aRR = 0.704, 95% CI 0.225–2.204).Conclusions: First‐trimester PSE exposure was not an independent risk factor for major congenital malformations, either overall or by organ system.
- Open Access
- 6 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1780-1789
Papaverine safety during pregnancy: Insights from a large population‐based cohort of pregnancies
Aims: Papaverine hydrochloride functions as an antispasmodic and vasodilator medication. Data concerning the teratogenic risk of papaverine is currently lacking. The aims of this paper are to examine the association between first‐trimester exposure to papaverine and major congenital malformations and the association between third trimester exposure to papaverine and late adverse pregnancy outcomes. Methods: We conducted a population‐based retrospective cohort study that included pregnant women 15–49 years old insured by ‘Clalit Health Services’ in southern Israel, who gave birth or had an elective pregnancy termination due to suspected fetal malformation at Soroka Medical Center between 1999 and 2017. Multivariate negative binomial regression models were used to examine the associations between papaverine during the first trimester and major congenital malformations, and between papaverine during the third trimester and late adverse pregnancy outcomes, adjusting for potential confounders. Results: The study included a total of 254 333 pregnancies, of which 3604 (1.41%) were exposed to papaverine during the first trimester, and 1253 (0.49%) during the third trimester. No significant associations were found between first‐trimester exposure to papaverine and total congenital major malformations or specific malformations according to organ systems in the multivariate analysis (adjusted RR for: total major malformations = 1.021; 95% confidence interval (CI) [0.895–1.165], cardiovascular = 1.073; 95% CI [0.905–1.273], central nervous system = 0.784; 95% CI [0.484–1.271], musculoskeletal = 0.823; 95% CI [0.588–1.153], gastrointestinal = 0.887; 95% CI [0.457–1.718], genitourinary = 1.076; 95% CI [0.805–1.438]). Additionally, we did not detect significant associations between third‐trimester exposure to papaverine and late adverse pregnancy outcomes. Conclusions: Exposure to papaverine during pregnancy was not associated with adverse pregnancy outcomes in the population studied, compared with non‐exposed pregnancies.
- 6 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1780-1789
Open AccessPapaverine safety during pregnancy: Insights from a large population‐based cohort of pregnancies
Aims: Papaverine hydrochloride functions as an antispasmodic and vasodilator medication. Data concerning the teratogenic risk of papaverine is currently lacking. The aims of this paper are to examine the association between first‐trimester exposure to papaverine and major congenital malformations and the association between third trimester exposure to papaverine and late adverse pregnancy outcomes. Methods: We conducted a population‐based retrospective cohort study that included pregnant women 15–49 years old insured by ‘Clalit Health Services’ in southern Israel, who gave birth or had an elective pregnancy termination due to suspected fetal malformation at Soroka Medical Center between 1999 and 2017. Multivariate negative binomial regression models were used to examine the associations between papaverine during the first trimester and major congenital malformations, and between papaverine during the third trimester and late adverse pregnancy outcomes, adjusting for potential confounders. Results: The study included a total of 254 333 pregnancies, of which 3604 (1.41%) were exposed to papaverine during the first trimester, and 1253 (0.49%) during the third trimester. No significant associations were found between first‐trimester exposure to papaverine and total congenital major malformations or specific malformations according to organ systems in the multivariate analysis (adjusted RR for: total major malformations = 1.021; 95% confidence interval (CI) [0.895–1.165], cardiovascular = 1.073; 95% CI [0.905–1.273], central nervous system = 0.784; 95% CI [0.484–1.271], musculoskeletal = 0.823; 95% CI [0.588–1.153], gastrointestinal = 0.887; 95% CI [0.457–1.718], genitourinary = 1.076; 95% CI [0.805–1.438]). Additionally, we did not detect significant associations between third‐trimester exposure to papaverine and late adverse pregnancy outcomes. Conclusions: Exposure to papaverine during pregnancy was not associated with adverse pregnancy outcomes in the population studied, compared with non‐exposed pregnancies.